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Matrix metalloproteinases and TIMPs in cultured C57BL16J-cpk kid-
ney tubules. Restructuring of basement membranes is a hallmark of the
pathology of renal cystic disorders. Here, we present findings consistent
with the view that basement membrane degradation by matrix metallo-
proteinases (MMPs) may contribute to abnormal basement membrane
structure in polycystic kidney disease. Cells from cystic kidney tubules
embedded in collagen gels appeared to migrate through the gel. This
migration through collagen indicated that these cells could degrade the
matrix. To examine this activity, we cultured cystic kidney tubules derived
from the C57BL/6J cpklcpk mouse, a hereditary model of polycystic kidney
disease, and assayed conditioned medium for the presence of MMPs and
tissue inhibitors of metalloproteinases (TIMPs). The conditioned medium
from the cystic tubules contained higher than normal levels of MMP-9,
MMP-2, and MMP-3 as well as TIMP-1 and TIMP-2. A 101 kDa protease
was present equally in cystic and control cultures and although inhibited
by EDTA, it was not inhibited by TIMPs, nor activated by the mercurial
compound APMA. These data suggest that cystic kidney tubules synthe-
size and secrete high levels of MMP5 which may then participate in the
restructuring of the tubular basement membrane.
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common hereditary renal disease. ADPKD is characterized
by the formation of multiple fluid-filled cysts that are derived from
tubule epithelium. A cyst is thought to originate as a small dilation
of a nephron segment, progress to a bulge in the tubule wall and
finally become a fluid-filled sac completely separated from the
nephron [1]. Cyst formation appears to involve basement mem-
brane remodeling, cell proliferation and fluid secretion [2—51.
Abnormal basement membrane structure has been observed both
in vivo and in cultured cells of cystic kidney tubules [6—8]. At least
some of the aberrant structure results from abnormal synthesis of
basement membrane components such as collagen IV, laminin,
fibronectin and proteoglycans [9—12], but degradation of certain
basement membrane proteins may also be an important factor.
A number of protcinases have been shown to degrade the
components of basement membrane in vitro [13]. Among them, a
group of mctalloproteinases termed matrix metalloproteinases
(MMP5) or matrixins, is considered to play a key role in extracel-
lular matrix catabolism as the MMPs are secreted from the cells
and act on the matrix at a physiological pH [14, 15]. Currently
eleven members of the matrixin family have been identified and
characterized [reviewed in 14]: three collagenases [interstial col-
lagenase (MMP-1), neutrophil collagenase (MMP-8) and collage-
nase 3 (MMP-13) [16]], two gelatinases [gelatinase A (MMP-2)
and gelatinase B (MMP-9)], two stromelysins [stromelysin 1
(MMP-3) and stromelysin 2 (MMP-10)], matrilysin (MMP-7),
stromelysin 3 (MMP-11), macrophage metalloelastase (MMP-12)
[17, 18] and membrane-type MMP (MT-MMP) [19—221. All
MMPs except stromelysin 3 (MMP-11) [23], are secreted from the
cell in an inactive proenzyme form and are activated extracellu-
larly. Once activated, the activity of MMPs is regulated by specific
endogenous inhibitors, TIMPS (TIMP-1, TIMP-2 and TIMP-3) or
a general plasma proteinase inhibitor, a2-macroglobulin. Activa-
tion and the balance between the matrix-degrading MMPs and
their inhibitors are important parameters for the eventual break-
down of extracellular matrix components.
In primary culture studies of cystic kidney tubules from the
C57BL/6J-cpk mouse model of PKD we observed that the tubule
cells readily migrated through the extracellular matrix in which
they were embedded. We examined the conditioned medium from
these cultured tubules and found high levels of MMPs including
MMP-2 (72 kDa gelatinase A), MMP-9 (92 kDa gelatinase B) and
MMP-3 (55 kDa stromelysin-1). High levels of TIMP-1 and
TIMP-2 in the cystic medium indicate that the MMPs are tightly
regulated. These results suggest that degradation of basement
membrane components may contribute to the abnormal basement
membrane structure associated with in vivo cyst formation.
Methods
Reagents and materials
Collagen I (Vitrogen) was obtained from Cclltrix; Matrigel was
from Collaborative Research. ProMMP-2 was purified from the
culture medium of human cervical fibroblast cells [23, 24]. Phe-
nylmethane-sulfonylfiouride (PMSF), 4-aminophenylmercuric ac-
etate (APMA), gelatin, and alpha-casein were from Sigma (St.
Louis, MO, USA). [32P] cytidine 5' triphosphate was from
NEN/Dupont (Boston, MA, USA).
Animals
A colony of C57BL/6J-cpk mice is maintained at the University
of Kansas Medical Center. Cystic mice are produced from matings
of heterozygous parents. Cystic mice (cpklcpk) are identified at
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Fig. 1. Cultured tubule cells from kidneys of the C57BLI6J-cpk mouse show
extensive migration through the geL Tubules from three wecks old normal
(A-C) or cystic (D-G) mice were embedded in a mix of Matrigel and
collagen 1(1:9 wt/wt) and cultured for 2 (A, D), 6 (B, E), 8 (G), 9 (C), or
10 (F) days. The culture medium was changed daily. An arrowhead points
to aggregated cystic cells (E); an asterisk (*) shows an area of collagen
matrix devoid of cells (G). Magnification: panels A through F, lox; panel
G, 4x.
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two or three weeks of age by palpating for enlarged kidneys. The
phenotypically normal littermates of the cystic cpk/cpk animals are
used as experimental controls and include both homozygous
(+1+) and heterozygous (cpk/+) animals.
Cultured kidney tubules from the C57BLI6J-cpk mouse
Mice were euthanized with ether, immersed in ethanol, and
their kidneys were removed aseptically. Kidneys were washed in
DMEM/F12 and minced. The kidneys from one animal were
incubated at 37°C for two to three hours (no longer than 2 hr for
normal whole kidney) in 10 ml collagenase solution: 1 mg/ml
collagenase IV (Worthington) and 1 mg/mI egg white trypsin
inhibitor (Sigma). The tissue was shaken vigorously every 15
minutes. Released tubules were harvested by centrifugation for
two minutes at 200 x g, then washed once in DMEM/F12.
Tubules were either plated directly for monolayer cultures or
embedded within a matrix collagen I-medium solution [lx
DMEM/F12 medium, 10 mrvt HEPES pH 7.4, 0.25% NaHCO3, 7
mM NaOH and collagen I (final collagen concentration of 1.5
mg/ml)]. The collagen I-medium solution was kept on ice and
mixed with Matrigel in a Matrigel:collagen I-medium ratio of 1:1
or 1:9 (wt/wt). Kidney tubule pieces were counted with a hemo-
cytometer and 12,500 pieces were dispersed into I ml of the
matrix mix and incubated at 37°C for 30 minutes to allow the
matrix gel to solidify. The solid matrix was then overlaid with 1 ml
of defined medium consisting of DMEM/F12, 15 mM HEPES pH
7.4, 20 ifiM NaHCO3, 5 sg/ml insulin, 5 jsg/ml transferrin, 5 X
1012 M tri-iodothyronine, 50 flM hydrocortisone (HC), 25 ng/ml
prostaglandin E1 (PGE1), 10 U/ml penicillin, and 10 g/m1
streptomycin [25—271.
RNA analysis
For RNA analysis, kidney tubules were subcultured overnight
on collagen I coated plates. Cells were then released, counted with
a hemocytometer, and plated at a density of 1.5 X 106 cells per 75
cm2 substrate-coated flask. After five days growth, the cells were
confluent and RNA was isolated by the method of Chomczynski
and Sacchi [28] with modifications to remove polysaccharide-like
material [291. Total RNA was fractionated on a 2.2 Ni formalde-
hyde, 1% agarose gel, blotted to GeneScreen Plus, and baked.
The blot was hybridized with 106 cpm/ml of probe in a 40%
formamide buffer solution (5% dextran sulfate, 1 M NaC1, 1%
SDS, 50 jg/ml tRNA, and 40% formamide) overnight at 65°C.
The probe was synthesized using a cDNA clone of human MMP-2
and radiolabeled with [a32P] cytidine to a specific activity (as
assayed by TCA precipitation) of 108 cpm/g of template DNA.
The blot was washed for 60 minutes in 0.3 X SSC, 0.1% SDS, and
for two 60 minute periods in 0.1 X SSC, 0.1%SDS. (1 x SSC is
0.15 M NaCl, 0.015 M sodium citrate; and 1 X Denhardt's solution
is 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum
albumin). Dupont Reflection NEF 496 film was used for autora-
diography.
Zymography
Gelatin zymography was performed essentially as described by
Hibbs et al [30]. Samples were mixed with SDS!PAGE sample
buffer and subjected to electrophoresis on an SDS/polyacrylamide
(7%) gel containing 0.8 mglml of gelatin, under non-reducing
conditions at room temperature. The buffer systems used were as
described by Bury [31], a modification of the 2-amino-2 methyl-
propane-1,2-diol/glycine/HC1 discontinuous system of Wyckoff,
Rodbard and Chramback [32]. Following electrophoresis the gel
was washed 4x in wash buffer [0.1 M Tris HC1 pH 7.6,5 mM CaCI2,
1 I.LM ZnC12, 0.02% NaN3, 2.5% Triton X-100], for 15 minutes
each time. The gel was then incubated at 37°C overnight (18 hr)
in wash buffer without Triton X-100, and stained with Coomassie
Brilliant Blue R-250. Enzymatic activity was seen as negatively
stained bands. The zymography gel was then scanned by an Epson
ES-1200C scanner using the Adobe Photo Shop computer pro-
gram to preserve the data and generate the figures. Casein
zymography was performed essentially the same as gelatin zymog-
raphy except that the gel contained 0.8 mg/mI of casein.
Detection of TIMPs by reverse zymography
The assay procedures were very similar to gelatin zymography,
except a resolving SDS/polyacrylamide gel (10% acrylamide) was
supplemented with proMMP-2 at a concentration of 1.2 .tg/ml.
The procedure allowed proMMP-2 activated by SDS to digest the
gelatin except in zones where MMP-2 inhibiting activities were
present.
Results
Extracellular matrix degradation by cultured tubules
When kidney tubules from cystic (cpk/cpk) mice were cultured
in gels containing collagen I, Matrigel, or mixtures of the two, the
cells of the dispersed tubules migrated extensively through the
extracellular matrix. Figure 1 shows a time course of cultured
kidney tubules embedded in a mixture of collagen I and Matrigel.
Tubule pieces of comparable size from whole normal or cystic
kidneys were counted and randomly dispersed throughout the
matrix. By day 6, numerous cell aggregates, appearing as dark
masses with spike-like projections, were seen in the cystic cultures
(Fig. 1 E-G). By day 8, migrating cystic cells were aggregated into
approximately one tenth the area of the well, leaving the remain-
der completely devoid of cells (Fig. 1G). The migration and
aggregation of the cystic cells through the collagen gel suggested
that these cells may produce matrix-degrading MMPs.
Secreted proteinases
We examined conditioned culture medium for proteinases that
may be involved in matrix degradation. The medium was changed
after two days in culture; 65 hours later (when cultures were 5
days old) medium was collected and subjected to zymography. To
insure that equal samples were being compared, we loaded equal
amounts of protein (3.75 jig/well) in each lane. Figure 2A shows
a gelatin zymograph of conditioned medium (CM) from tubule
cultures. Major proteases migrated as 101, 92, and 68 kDa protein
bands under non-reducing conditions. The 101 kDa band was
detected in both normal and cystic samples at a similar level. The
92 and 68 kDa bands are present at higher levels in the cystic
compared with the normal samples. The migration of these two
bands under non-reducing conditions, suggested that they may be
proMMP-9 and proMMP-2, respectively. As expected, the mouse
proMMP-9 band migrates slightly slower than the human as the
proteins differ in molecular weight [33] (92 kDa for mouse, 88
kDa for human in non-reducing conditions). Zymography with a
casein substrate revealed the presence of a band in cystic medium
corresponding in molecular weight to proMMP-3 (Fig. 2B).
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Fig. 3. The major protease bands (101, 92, and 68 kDa) are not inhibited by serine or cysteine protease inhibitors but are inhibited by EDTA. Gelatin
zymography gels were washed and incubated in the presence of 10 mvt iodoacetamide, 2 mvi phenylmethane-sulfonylfiouride (PMSF), or 20 mM EDTA.
Conditioned medium samples, marker, amount loaded per lane, and incubation time were the same as in Figure 2A.
All three gelatinolytic bands detected by zymography (101, 92
and 68 kDa) were inhibited by 20 msi EDTA, but not by 10 mM
iodoacetamide or 2 mivi phenylmethane-sulfonylfiouride (PMSF)
indicating that they are metalloendopeptidases (Fig. 3).
Identification of MMP-2 and MMP-9
To further define whether the proteases detected at 101, 92 and
68 kDa are members of the matrixin family, zymographic lysis
procedures were carried out in the presence of TIMP-1. As shown
in Figure 4, the 92 and 68 kDa bands were inhibited by TIMP-1
whereas the 101 kDa band was resistant. These results suggest
that the 92 and 68 kDa bands are zymogen forms of MMP-9 and
MMP-2, respectively [34, 35].
Activation of the 92 and 68 kDa bands by APMA
MMP precursors, proMMPs, are commonly activated by mer-
curial compounds (APMA) in vitro. We therefore treated the CM
with 1.5 mivt APMA for 30 minutes and subjected it to gelatin
Fig. 2. A. Gelatin zymography of conditioned medium from kidney tubule cultures esta blished from three weeks old mice. 6250 tubule pieces per cm2 from
2 cystic or 4 normal mice were either cultured on plastic or embedded (12,500 tubule pieces/mI of gel) in a mixture of Matrigel and collagen I at a ratio
of 1:1 or 1:9 wt/wt. ECM alone is extracellular matrix without cells. The marker (M) is conditioned medium from HT1O8O cells which synthesize and
secrete large amounts of proMMP-9 and -2. Abbreviations are: N, normal; C, cystic. B. Casein zymography of conditioned medium from kidney tubule
cultures established from three weeks old mice. The marker (M) is APMA-activated and purified human MMP-3. Media was collected from tubules
cultured for 2, 5, and seven days in a Matrigel/collagen I ratio (1:9 wt/wt). The medium from the seven days cultures had been conditioned for 48 hours.
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Fig. 4. Inhibition of MMPs in conditioned medium by TIMP-]. Duplicate
conditioned medium samples were collected from cystic tubules grown on
plastic and subjected to gelatin zymography. Following electrophoresis,
the gel was divided and one sample (labeled +) had 5 jg/ml TIMP-1
added to the wash and incubation buffers.
zymography (Fig. 5). However, we did not see any shift in band
size to indicate that the proMMPs were activated by APMA.
Instead, the band intensity in the 101 and 68 kDa species was
partially reduced and the 92 kDa species disappeared after
APMA treatment. As proMMP-9 can be activated by MMP-3
[36—381, the samples were treated with MMP-3 which converted
the 92 kDa species to 85 kDa (compare the "untreated" with the
"MMP-3" lane in the cystic samples), consistent with the 92 kDa
species being mouse MMP-9. The 68 kDa species remained
unaffected by MMP-3 alone; however, addition of MMP-3 prior to
APMA treatment converted the 68 kDa species to 62 kDa
consistent with this species being MMP-2. That both MMP-3 and
APMA treatment were required to convert the 68 kDa
proMMP-2 to the activated 62 kDa MMP-2 suggests that
proMMP-2 is complexed with TIMP [241. Apparently treatment
with APMA alone, as well as MMP-3 and APMA degrades the 92
kDa proMMP-9 and results in decreased proMMP-9 band inten-
sity. Although the band intensity is reduced by some treatments,
the size of the 101 kDa species is unaffected by treatment with
APMA, MMP-3 or MMP-3 and APMA. This, along with its
insensitivity to TIMP-1, shows that the 101 kDa band represents
an unknown protease that is unlikely to be a member of the MMP
family.
MMP-2 mR/VA in cystic cultured cells
RNA was isolated from kidney cells grown as a monolayer
either on plastic, or on mixes of Matrigel and collagen I, 1:1 or 1:9
wt/wt (Fig. 6). The substrate apparently influences the steady state
levels of MMP-2 mRNA in both cell types; however, levels in
cystic cells are 2.5, 2, and 3.2 times higher than normal on plastic,
and on 1:1 and 1:9 Matrigel/collagen I mixes, respectively. This is
consistent with the zymography data (Fig. 2A). MMP-9 mRNA
was not detected by Northern blot analysis due to the sensitivity of
this technique (data not shown).
Identification of TIMPs
CM samples were subjected to reverse zymography to identify
TIMPs. Bands corresponding to the TIMP-1 and TIMP-2 markers
were seen in the samples from cystic tubules (Fig. 7). The TIMP
bands were most intense in CM from tubules cultured on plastic
and embedded in the 1:1 ratio of Matrigel and collagen I (wt/wt).
As the proportion of Collagen I in the cultures increased (1:9), the
amount of TIMPs present in the CM decreased, suggesting that
the matrix composition affected TIMP synthesis in the cystic
tubules. In all cell culture substrates, the quantity of TIMP-1 was
greater than TIMP-2.
As the predominant MMPs in the cystic conditioned medium
are the inactive zymogen forms of MMP-2 and -9, and with
increased amounts of TIMPs in the cystic conditioned medium, it
appears that matrix degradation is tightly regulated in this in vitro
system. Consistent with this observation is the fact that the cystic
conditioned medium had no detectable net activity (data not
shown).
Discussion
After observing the migration and aggregation of cells from
cystic kidney tubules embedded in extracellular matrix, we exam-
ined matrix degrading metalloproteinases (MMPs) in the culture
medium. Cultured cystic tubules from the C57BL/6J-cpk mouse
kidneys were found to secrete greater than normal amounts of the
matrix metalloproteinases, MMP-2, -9, and -3 into the culture
medium. These MMPs are present mainly in the inactive, zymo-
gen form. Tissue inhibitors of MMPs, TIMP-1 and -2 are also
secreted into the medium by the cultured cystic tubules. Similar to
other culture systems [39—42], proMMP-2 and -9 may be bound
to TIMPs. As demonstrated in Figure 5, preincubation with
MMP-3 was required to activate proMMP-2, presumably because
proMMP-2 in the media forms a complex with TIMP-2 [241.
Although we did not detect any TIMPs in the normal samples by
reverse zymography (Fig. 7), they appear to be present at very low
concentrations. This is evident from the fact that the conversion of
proMMP-2 in the normal sample by APMA was prevented (Fig. 5).
By examining conditioned medium we focused on secreted
matrix metalloproteinases; therefore levels of membrane-bound
metalloendopeptidases such as MT-MMP and meprin were not
investigated in this study. It is possible that meprin, which has
been reported to degrade laminin, type IV collagen and fibronec-
tin [43, 4I, may also contribute to matrix remodeling.
Although cystic tubules secreted very high levels of pro MMPs-2
and -9 into the culture medium, it appeared that activation and
activity of these MMPs were tightly controlled as the cystic
conditioned medium had no net protease activity. Therefore, the
migration and aggregation was likely the result of localized MMP
activity. MT-MMPs have been identified and are implicated in
proMMP-2 activation [19—22], MT-MMPs contain a transmem-
brane domain and have been localized to the cell surface [45].
Further, from studies of tumor metastasis, it is known that
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Fig. 5. Activation of proMMPs. Conditioned medium samples were from normal (N) or cystic (C) tubules cultures. Tubules were fed after two days in
culture. Sixty-five hours later medium was collected and subjected to zymography. Conditioned medium samples were incubated with 1 mrvi APMA for
30 minutes, with activated MMP-3 (1 eg/ml) for one hour, or with MMP-3 (1 gIml) for one hour followed by 1 mM APMA for 30 minutes prior to
electrophoresis. The marker is purified proMMP-2.
Plastic 1:1 1:9
I II II I
N C N C N C
+- 28S
MMP-2 -s
÷- 18S
28 S Fig. 6. Northern blot analysis of MMP-2 rnRNA.Murine kidney tubule cells were subcultured on
substrates of either plastic of mixes of Matrigel:
collagen I. RNA was isolated and 5 jsg were
loaded in each lane. The relative density was
18 S analyzed by densitometric software, IPLab Gel
(Signal Analytics Corp, Vienna, VA, USA), and
standardized to the 28 and 18S hands of the
methylene blue stained blot. The density of the
Relative normal on plastic sample was assigned the
density 1.0 2.5 1 .9 3.8 1 .8 5.8 value of 1.0. Abbreviations are: N, normal; C,
proMMP-2 interacts with a receptor molecule on the plasma the immediate vicinity of the cell surface, regardless of where the
membrane [46, 47]. A mechanism in which proMMP-2 is bound by proMMP-2 was synthesized. The high levels of proMMP-2 in the
a cell surface receptor, then activated by a membrane-bound cystic culture medium ensure that proMMP-2 is readily accessible
MT-MMP would restrict extracellular matrix degradation to to receptor and activator molecules. In vitro, MMP activation may
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focus basement membrane degradation to the tip of the tubule so
that tubule extension can occur. In vivo, MMP activation along the
length of the cystic tubule could initiate tubular dilation, hypoth-
esized to be the first step in cyst formation [1].
However, the effect of MMP activity may be somewhat more
complex. In the kidney, the distribution of basement membrane
components is heterogenous, and differing proportions of compo-
nents along the renal tubule may account for the different
properties of the tubular segments [481.A change in the ratio of
basement membrane constituents either by abnormal synthesis of
basement membrane components or by abnormal degradation
may give faulty signals to the cells and result in a loss of
differentiated characteristics. Altered synthesis (collagen IV, lami-
nm and proteoglycans) [9, 10, 49] as well as uneven distribution
(collagen IV and laminin) [9, 501 and decreased quantities
(heparan sulfate-proteoglycans) [511 of basement membrane com-
ponents have been observed in various forms of PKD. The
enhanced MMP-2 production may account for abnormal distribu-
tion and decreased quantities of some of these components.
The basement membrane abnormalities that are so widespread
in renal cystic diseases [52] suggest that cell-matrix interactions
are critical to cyst formation. In fact, one early hypothesis of the
etiology of PKD suggested that the ADPKD mutation might be an
altered basement membrane component [2—5, 53—55]. Now that
the ADPKD gene has been identified and sequenced, it appears
that the protein is a membrane-bound receptor-like molecule
[56—58]. However, analysis of the predicted amino acid sequence
indicates the presence of domains that may interact with base-
ment membrane components [59]. Therefore, it appears that the
basement membrane may be an important participant in cyst
formation in ADPKD.
In summary, basement membrane abnormalities may develop
through aberrant synthesis of basement membrane components,
or, as has been hypothesized by several researchers, by aberrant
catabolism and turnover of basement membrane [60—64]. Here
we report that cultured kidney tubules from C57BLI6J-cpk cystic
mice produce very high levels of MMP-2, -3 and -9 as well as
TIMP-1 and -2. Our data suggest that basement membrane
abnormalities associated with cystic kidney tubules may indeed
result from aberrant degradation as well as from abnormal
synthesis of basement membrane components.
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